| 1 | overall | 44,776 |
| 2 | over-all | 61 |
| 3 | single-procedure | 16 |
| 4 | crc-specific | 6 |
| 5 | gms2 | 6 |
| 6 | weibullian | 5 |
| 7 | aaa-specific | 4 |
| 8 | african-american/black | 4 |
| 9 | twenty-four-week | 4 |
| 10 | 99mtc-uptake | 3 |
| 11 | antioedematous | 3 |
| 12 | echo/thrive | 3 |
| 13 | eelgrass | 3 |
| 14 | ifct-gfpc | 3 |
| 15 | overtriage | 3 |
| 16 | p38-nf-κb | 3 |
| 17 | surgeon-reported | 3 |
| 18 | convulsion/seizure | 2 |
| 19 | four-member | 2 |
| 20 | ge/g | 2 |
| 21 | sga-infants | 2 |
| 22 | std-infected | 2 |
| 23 | stratum-adjusted | 2 |
| 24 | stress/defense | 2 |
| 25 | temperature-associated | 2 |
| 26 | 0ne-year | 1 |
| 27 | 1,3,5,9-year | 1 |
| 28 | 110-week | 1 |
| 29 | 2-/3-year | 1 |
| 30 | 26.9-month | 1 |
| 31 | acute-rejection-free | 1 |
| 32 | as-one-goes | 1 |
| 33 | cisplatin-attributable | 1 |
| 34 | complication/utility-adjusted | 1 |
| 35 | cox-adjusted | 1 |
| 36 | cranial-to-caudal | 1 |
| 37 | cystectomy-free | 1 |
| 38 | diseasefree | 1 |
| 39 | fmc.to | 1 |
| 40 | intra-macrophage | 1 |
| 41 | kidney/patient | 1 |
| 42 | mae-free | 1 |
| 43 | osteonecrosis-free | 1 |
| 44 | physician-treated | 1 |
| 45 | post-eavr | 1 |
| 46 | post-lead-time | 1 |
| 47 | post-recurrence | 1 |
| 48 | pre-analgesia | 1 |
| 49 | proteinuria-free | 1 |
| 50 | psa-free | 1 |
| 51 | pyelonephritis-free | 1 |
| 52 | scd-free | 1 |
| 53 | semicaptive | 1 |
| 54 | sildenafil-mediated | 1 |
| 55 | tagged-particle | 1 |
| 56 | thirteen-year | 1 |
| 57 | weibull-distribution | 1 |
| 1 | 0ne-year | 1 |
| 2 | 1,3,5,9-year | 1 |
| 3 | 110-week | 1 |
| 4 | 2-/3-year | 1 |
| 5 | 26.9-month | 1 |
| 6 | 99mtc-uptake | 3 |
| 7 | aaa-specific | 4 |
| 8 | acute-rejection-free | 1 |
| 9 | african-american/black | 4 |
| 10 | antioedematous | 3 |
| 11 | as-one-goes | 1 |
| 12 | cisplatin-attributable | 1 |
| 13 | complication/utility-adjusted | 1 |
| 14 | convulsion/seizure | 2 |
| 15 | cox-adjusted | 1 |
| 16 | cranial-to-caudal | 1 |
| 17 | crc-specific | 6 |
| 18 | cystectomy-free | 1 |
| 19 | diseasefree | 1 |
| 20 | echo/thrive | 3 |
| 21 | eelgrass | 3 |
| 22 | fmc.to | 1 |
| 23 | four-member | 2 |
| 24 | ge/g | 2 |
| 25 | gms2 | 6 |
| 26 | ifct-gfpc | 3 |
| 27 | intra-macrophage | 1 |
| 28 | kidney/patient | 1 |
| 29 | mae-free | 1 |
| 30 | osteonecrosis-free | 1 |
| 31 | over-all | 61 |
| 32 | overall | 44,776 |
| 33 | overtriage | 3 |
| 34 | p38-nf-κb | 3 |
| 35 | physician-treated | 1 |
| 36 | post-eavr | 1 |
| 37 | post-lead-time | 1 |
| 38 | post-recurrence | 1 |
| 39 | pre-analgesia | 1 |
| 40 | proteinuria-free | 1 |
| 41 | psa-free | 1 |
| 42 | pyelonephritis-free | 1 |
| 43 | scd-free | 1 |
| 44 | semicaptive | 1 |
| 45 | sga-infants | 2 |
| 46 | sildenafil-mediated | 1 |
| 47 | single-procedure | 16 |
| 48 | std-infected | 2 |
| 49 | stratum-adjusted | 2 |
| 50 | stress/defense | 2 |
| 51 | surgeon-reported | 3 |
| 52 | tagged-particle | 1 |
| 53 | temperature-associated | 2 |
| 54 | thirteen-year | 1 |
| 55 | twenty-four-week | 4 |
| 56 | weibull-distribution | 1 |
| 57 | weibullian | 5 |
| 1 | gms2 | 6 |
| 2 | pre-analgesia | 1 |
| 3 | p38-nf-κb | 3 |
| 4 | aaa-specific | 4 |
| 5 | crc-specific | 6 |
| 6 | ifct-gfpc | 3 |
| 7 | physician-treated | 1 |
| 8 | temperature-associated | 2 |
| 9 | sildenafil-mediated | 1 |
| 10 | std-infected | 2 |
| 11 | surgeon-reported | 3 |
| 12 | stratum-adjusted | 2 |
| 13 | cox-adjusted | 1 |
| 14 | complication/utility-adjusted | 1 |
| 15 | post-recurrence | 1 |
| 16 | proteinuria-free | 1 |
| 17 | psa-free | 1 |
| 18 | scd-free | 1 |
| 19 | mae-free | 1 |
| 20 | acute-rejection-free | 1 |
| 21 | osteonecrosis-free | 1 |
| 22 | pyelonephritis-free | 1 |
| 23 | cystectomy-free | 1 |
| 24 | diseasefree | 1 |
| 25 | intra-macrophage | 1 |
| 26 | overtriage | 3 |
| 27 | 99mtc-uptake | 3 |
| 28 | cisplatin-attributable | 1 |
| 29 | tagged-particle | 1 |
| 30 | post-lead-time | 1 |
| 31 | single-procedure | 16 |
| 32 | convulsion/seizure | 2 |
| 33 | stress/defense | 2 |
| 34 | echo/thrive | 3 |
| 35 | semicaptive | 1 |
| 36 | ge/g | 2 |
| 37 | 26.9-month | 1 |
| 38 | african-american/black | 4 |
| 39 | 110-week | 1 |
| 40 | twenty-four-week | 4 |
| 41 | cranial-to-caudal | 1 |
| 42 | over-all | 61 |
| 43 | overall | 44,776 |
| 44 | weibullian | 5 |
| 45 | weibull-distribution | 1 |
| 46 | fmc.to | 1 |
| 47 | 2-/3-year | 1 |
| 48 | 1,3,5,9-year | 1 |
| 49 | 0ne-year | 1 |
| 50 | thirteen-year | 1 |
| 51 | four-member | 2 |
| 52 | post-eavr | 1 |
| 53 | as-one-goes | 1 |
| 54 | eelgrass | 3 |
| 55 | sga-infants | 2 |
| 56 | antioedematous | 3 |
| 57 | kidney/patient | 1 |